Finkelmeier, Fabian, Scheiner, Bernhard, Leyh, Catherine, Best, Jan ORCID: 0000-0003-2074-0930, Fruendt, Thorben Wilhelm, Czauderna, Carolin, Beutel, Alica, Bettinger, Dominik, WeiSS, Johannes, Meischl, Tobias ORCID: 0000-0002-1716-9166, Kuetting, Fabian, Waldschmidt, Dirk-Thomas, Radu, Pompilia, Schultheiss, Michael, Peiffer, Kai-Henrik, Ettrich, Thomas J., Weinmann, Arndt ORCID: 0000-0003-1198-1716, Wege, Henning, Venerito, Marino, Dufour, Jean-Francois, Lange, Christian M., Pinter, Matthias and Waidmann, Oliver (2021). Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort. Liver Cancer, 10 (4). S. 360 - 370. BASEL: KARGER. ISSN 1664-5553

Full text not available from this repository.

Abstract

Background and Aims: The multikinase inhibitor cabozantinib has been approved for hepatocellular carcinoma (HCC) previously treated with sorafenib. We report safety and efficacy data of an international, multicenter, real-life cohort of patients with advanced HCC treated with cabozantinib. Methods: Patients with HCC who were treated with cabozantinib were retrospectively identified across 11 centers in Austria, Switzerland, and Germany. Patients' characteristics, adverse events, duration of treatment and overall survival (OS) data were analyzed until April 1, 2020. Results: Eighty-eight patients from 11 centers were included. The predominant underlying liver diseases were NAFLD/NASH in 26 (30%) and hepatitis C infection in 21 (24%) patients. Seventy-eight patients (89%) were classified as Barcelona clinic liver cancer (BCLC) stage C. Sixty patients (68%) were Child-Pugh A, whereas 22 (25%) were Child-Pugh B, respectively. Cabozantinib was used as systemic second- and third-line or later treatment in 41 (47%) and 46 (52%) patients, respectively. The following best responses under cabozantinib were documented: partial response in 6 (7%), stable disease in 28 (32%), and progressive disease in 28 (32%) patients, respectively. Fifty-two patients (59%) died during follow-up. The median OS from start of cabozantinib treatment was 7.0 months in the entire cohort and 9.7 months in Child-Pugh A patients, while Child-Pugh B patients had a median OS of 3.4 months, respectively. Thirty-seven (42%) patients fulfilled the CELESTIAL inclusion and exclusion criteria, showing a median OS of 11.1 months. Most common adverse events were fatigue (15.6%) and diarrhea (15.6%). Conclusion: Cabozantinib treatment was effective, safe, and feasible in patients with advanced HCC in patients with compensated cirrhosis. Patients in the real-life setting had more advanced liver disease - in which 25% of patients were Child-Pugh B. However, OS in patients with Child-Pugh A cirrhosis was similar to that reported in the phase 3 trial (CELESTIAL).

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Finkelmeier, FabianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Scheiner, BernhardUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Leyh, CatherineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Best, JanUNSPECIFIEDorcid.org/0000-0003-2074-0930UNSPECIFIED
Fruendt, Thorben WilhelmUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Czauderna, CarolinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Beutel, AlicaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bettinger, DominikUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
WeiSS, JohannesUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Meischl, TobiasUNSPECIFIEDorcid.org/0000-0002-1716-9166UNSPECIFIED
Kuetting, FabianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Waldschmidt, Dirk-ThomasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Radu, PompiliaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schultheiss, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Peiffer, Kai-HenrikUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ettrich, Thomas J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Weinmann, ArndtUNSPECIFIEDorcid.org/0000-0003-1198-1716UNSPECIFIED
Wege, HenningUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Venerito, MarinoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dufour, Jean-FrancoisUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lange, Christian M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pinter, MatthiasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Waidmann, OliverUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-603249
DOI: 10.1159/000515490
Journal or Publication Title: Liver Cancer
Volume: 10
Number: 4
Page Range: S. 360 - 370
Date: 2021
Publisher: KARGER
Place of Publication: BASEL
ISSN: 1664-5553
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
DOUBLE-BLIND; PATIENTS PTS; PHASE-III; SORAFENIB; PLACEBO; PHARMACOKINETICS; OUTCOMESMultiple languages
Oncology; Gastroenterology & HepatologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/60324

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item